BNET Industries
Market Cap:$263.3M
Last Fiscal Year Sales:$47.1M
- Public
- US
Dow Jones Description
We are a genetics company committed to providing genetic analysis products, services and diagnostic applications. Our products and services are designed to translate the results of genomic research into solutions for biomedical research, translational research, molecular medicine applications and research conducted in the agro (agricultural and livestock) industry. Our development efforts in various diagnostic applications include areas of noninvasive diagnostics in prenatal, oncology and infectious diseases and other disorders. Our proprietary MassARRAY system, comprised of hardware, software applications, consumable chips and reagents, is a high performance (in speed, accuracy and cost efficiency) nucleic acid analysis platform that quantitatively and precisely measures genetic target material and variations. Our MassARRAY research and development efforts are committed to producing new and improved components and applications that deliver greater system versatility and reduce the cost per data point generated. MassARRAY technology is widely accepted as a leading high-performance DNA analysis platform for the fine mapping genotyping and quantitative gene expression markets and is gaining traction in new developing markets, such as epigenomics and pathogen typing. Our customers include some of the worldwide premier clinical research laboratories, biotechnology companies and academic institutions, as well as various government agencies. ...
Number of Employees 248
Contact Information
3595 John Hopkins Ct
San Diego, California 92121-1331
(858) 202-9000
Peer Companies
NAICS Code : 541710
Recent Events
-
PicksThatMove.com Announces Investment Opinion on Sequenom Inc., Gabriel Resources Ltd., Rentech Inc., Imaging 3 Inc.,...
-
Sequenom Q3 Loss Widens - Update
-
Sequenom faces fraud suit from Xenomics
-
Sequenom, Ibis settle lawsuit
-
Sequenom names Maier as interim CFO
-
ATVI, RMBS, MRVL, SQNM, ERIC, AKAM With Highest Daily Short Volume On
-
Sequenom discloses probes following firings
-
Sequenom ousts CEO, other execs
-
Sequenom tumbles after execs fired amid test woes
-
Investors Remain Hopeful About Sequenom's Prospects
-
Sequenom Ousts CEO After Finding Errors, Inconsistencies In Down Syndrome Test; CFO Resigns
News & Analysis
Filter by
sequenom inc. and trader mark - All News and Analysis
Sequenom and the Small Cap Biotech Bipolar Experience
Trader Mark submits: Still keeping my eye on the Sequenom SQNM, but the whole idea with this name was to avoid the small cap "biotech" bipolar experience either a huge win or a huge loss. Unfortunately, this is what this has now turned to, a coin flip. Probably the most...
Sequenom Misses Earnings Again
Trader Mark submits:Sequenom SQNM reported Tuesday night, but as I said last quarter [Oct 30: Sequenom Misses But We Don't Really Care], and will say next quarter and the quarter after that ... earnings "today" don't mean diddly in this story. The main focus for Sequenom for now is cash...
Exact Sciences Plays Hard to Get with Sequenom
Trader Mark submits: I've asked mother market to drop Sequenom SQNM to $21 so I can reload the position - a bevy of limit orders waiting. Missed it by THAT much....Remember this will be a news event driven stock - end of January test results will cause a quite...
Sequenom Misses, but Who Cares?
Trader Mark submits: Near term results for Sequenom SQNM are really a moot point as we're looking to mid 2009 forward on this story; the main issue in this new and not so improved environment is making sure young companies have cash to get them to the point where they...
- 1



